癌症患者症状性亚急性硬膜下血肿的脑膜中动脉栓塞治疗
回顾性纳入23例癌症合并症状性亚急性硬膜下血肿患者,共行34次脑膜中动脉造影。技术成功率91.2%(31/34),中位手术时间61分钟,无进一步干预需要,不良事件率4.3%(1/23),结论认为该栓塞术似乎安全并与临床症状改善相关。
要点
- 癌症患者症状性亚急性硬膜下血肿行脑膜中动脉栓塞技术成功率91.2%(31/34)。
- 中位透视时间21.6分钟,中位参考剂量158 mGy,中位KAP 32.9 Gy·cm²。
- 不良事件率4.3%(1/23),8例(34.8%)随访期间死于癌症进展。
核心结论
- 脑膜中动脉栓塞治疗癌症患者症状性亚急性硬膜下血肿似乎安全,并与临床症状改善相关。
研究设计与样本
- 回顾性研究纳入23例连续患者(12男11女,中位年龄61岁,四分位距55.5-75.5),2022至2023年间共行34次脑膜中动脉造影。
- 10例(43.5%,10/23)为血液系统恶性肿瘤,7例(30.4%,7/23)曾接受手术。
关键影像表现/征象
- 中位硬膜下血肿厚度10.5 mm(7-12),中位血小板计数117 K/mcL(54.5-218)。
- 16例患者硬膜下血肿在中位59.5天(50-90)后消退;7例患者末次影像随访(中位24天,6.5-36.5)时血肿仍可见。
诊断标准与关键数值
- 技术成功率91.2%(31/34),因2例患者中3支脑膜中动脉未能识别。
- 中位手术时间61分钟(55.5-75.5),中位透视时间21.6分钟(15.5-31.8),中位参考剂量158 mGy(96-256),中位KAP 32.9 Gy·cm²(20.4-45.1)。
- 中位影像随访65天(36.5-190.5),中位临床随访163天(86-274)。
- 未发现失败预测因素;不良事件率1/23(4.3%)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The purpose of this study was to evaluate the technical and clinical success of middle meningeal artery (MMA) embolization performed for symptomatic subacute subdural hematoma (SDH) in patients with cancer.
METHODS: This study retrospectively included 23 consecutive patients (12 men, 11 women; median age 61 years, interquartile range: 55.5-75.5) who underwent 34 MMA angiograms for symptomatic SDH in 2022 and 2023. Median SDH thickness was 10.5 mm (7-12). Median platelet count was 117 K/mcL (54.5-218). 10 patients (43.5%, 10/23) had hematologic malignancies, seven patients (30.4%, 7/23) had surgery. Fluoroscopy time (FT), reference dose (RD), and kerma area product (Kap) were analyzed. Adverse events and outcomes were recorded.
RESULTS: The median imaging and clinical follow-up were 65 days (36.5-190.5) and 163 days (86-274), respectively. The technical success rate was 91.2% (31/34) as three MMA were not identified in two patients. Median procedure duration was 61 min (55.5-75.5). Median FT was 21.6 min (15.5-31.8); median RD was 158 mGy (96-256); and median Kap was 32.9 Gy.cm2 (20.4-45.1). No further intervention was needed. For 16 patients, SDH resolved after in median 59.5 days (50-90). For seven patients, SDH remained visible on the last imaging follow-up performed at 24 days in median (6.5-36.5). No predictive factor of failure was identified. The adverse event rate was 1/23 (4.3%). Eight patients (34.8%, 8/23) died during follow-up from progression of cancer.
CONCLUSION: MMA embolization of symptomatic SDH in patients with cancer appears safe and is associated with improvement in clinical symptoms.
引用
- O'Gorman J, Geevarghese R, Bodard S, et al. Embolization of Middle Meningeal Arteries for Symptomatic Subacute Subdural Hematoma in Patients with Cancer. Acad Radiol. 2024. PMID: 38702213. doi:10.1016/j.acra.2024.04.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。